dc.creatorMorri, Mauro Gaspar
dc.creatorCastellano, Patricia Margarita
dc.creatorLeonardi, Darío
dc.creatorVignaduzzo, Silvana Edit
dc.date.accessioned2019-10-23T21:01:58Z
dc.date.accessioned2022-10-15T03:29:10Z
dc.date.available2019-10-23T21:01:58Z
dc.date.available2022-10-15T03:29:10Z
dc.date.created2019-10-23T21:01:58Z
dc.date.issued2018-05
dc.identifierMorri, Mauro Gaspar; Castellano, Patricia Margarita; Leonardi, Darío; Vignaduzzo, Silvana Edit; First Development, Optimization, and Stability Control of a Pediatric Oral Atenolol Formulation; Springer; AAPS Pharmscitech; 19; 4; 5-2018; 1781-1788
dc.identifierhttp://hdl.handle.net/11336/87179
dc.identifier1530-9932
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4340189
dc.description.abstractLiquid formulations can be used in children of different ages by varying the volume of the administered dose in order to ensure an exact dosage. The aim of this work was to develop and to optimize a safe liquid atenolol formulation and to carry out the corresponding chemical and microbiological stability studies. A Plackett-Burman design was used to determine the factors that could be critical in the development of the formulations, and a central composite design was used to determine the optimal working conditions. As a result of these analyses, three formulations were selected and their stability studied in three storage conditions, 4, 25, and 40°C. After 6 months of stability testing, the optimal systems showed no pH change or atenolol loss; however, only glycerin-based formulations showed no microbial development. These systems, employing excipients in a range that the EMA has recommended, showed chemical and microbiological stability for at least 6 months even at the worst storage conditions.
dc.languageeng
dc.publisherSpringer
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1208/s12249-018-0992-5
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1208%2Fs12249-018-0992-5
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectATENOLOL
dc.subjectDEVELOPMENT
dc.subjectEXPERIMENTAL DESIGN
dc.subjectPEDIATRICS
dc.subjectSTABILITY
dc.titleFirst Development, Optimization, and Stability Control of a Pediatric Oral Atenolol Formulation
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución